Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries October 2026

https://www.eurordis.org/publications/timing-and-rate-of-reimbursement-for-cystic-fibrosis-modulator-therapies-in-eu-countries/ This article, published in ScienceDirect, examines cross-country differences in timing and rate of reimbursement for Cystic modulator therapies (CFTR modulators) and explores the determinants of reimbursement timelines across Europe. Among the paper’s co-authors is our former Patient Engagement & Therapeutic Development Director, Maria Cavaller Bellaubi. Although CFTR modulators are authorised at EU level, decisions on reimbursement are made nationally, leading to differences in when people living with cystic fibrosis can access these treatments.